ORAL FORMULATION COMPRISING NAFAMOSTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Title:

ORAL FORMULATION COMPRISING NAFAMOSTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Document Type and Number:

WIPO Patent Application WO/2022/065789

Kind Code:

A1

Abstract:

The present invention provides an oral formulation comprising nafamostat or a pharmaceutically acceptable salt as an active ingredient; and an acidifier as a stabilizer. The present invention also provides an oral formulation in a sustained release form or a controlled release form which comprises nafamostat or a pharmaceutically acceptable salt; an acidifier; and a water-soluble sustained release polymer. The oral formulation according to the present invention can be advantageously applied to the prevention or treatment of corona virus infection disease-19 (COVID-19).

More Like This:

JP2006508967	Oral testosterone donation system with improved sustained release
WO/2023/034844	DELAYED RELEASE NICLOSAMIDE FORMULATION
JP2022171508	METHOD FOR PRODUCING LINAGLIPTIN-CONTAINING PREPARATION HAVING EXCELLENT STABILITY AND UNIFORMITY

Inventors:

CHOI SOOK (KR)

Application Number:

PCT/KR2021/012537

Publication Date:

March 31, 2022

Filing Date:

September 15, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

IMDPHARM INC (KR)

International Classes:

A61K9/20; A61K9/24; A61K31/24; A61K47/12; A61P31/14

Foreign References:

KR20150083358A	2015-07-17
US20130225643A1	2013-08-29
US20170105938A1	2017-04-20

Other References:

WANG, M. ET AL.: "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2 019-nCoV) in vitro", CELL RESEARCH, vol. 30, no. 3, 4 February 2020 (2020-02-04), pages 269 - 271, XP037049320, DOI: 10.1038/s41422-020-0282-0
YAMAMOTO, M. ET AL.: "Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell - cell fusion assay", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 60, no. 11, 2016, pages 6532 - 6539, XP055536983, DOI: 10.1128/AAC.01043-16

Attorney, Agent or Firm:

OH, Kook-Jin (KR)

Download PDF:

View/Download PDF PDF Help

Previous Patent: ELECTRONIC DEVICE FOR RECEIVING OR TRANSMITTING RCS DATA, AND METHOD FOR OPERATING ELECTRONIC DEVICE

Next Patent: REFRIGERANT HEAT EXCHANGE SYSTEM USING CIRCULATION OF LIQUID MEDIUM